Proliferation of PBMC in Response to Anti-CD40 MoAb in the Presence of IL-4 or IL-13
| A Stimulus . | cpm of [3H]Thymidine Incorporated/Culture . | |||||||
|---|---|---|---|---|---|---|---|---|
| Controls . | Patients . | |||||||
| 1 . | 2 . | 3 . | 1 . | 2 . | 3 . | 4 . | 5 . | |
| Medium | 2,100 | 1,580 | 1,551 | 3,251 | 1,200 | 1,338 | 1,124 | 357 |
| Anti-CD40 + IL-4 | 11,692 | 10,162 | 37,743 | 82,844 | 9,359 | ND | 23,852 | 10,180 |
| Anti-CD40 + IL-13 | 7,955 | 6,170 | 21,335 | 92,562 | 12,639 | 32,485 | 18,219 | 7,655 |
| A Stimulus . | cpm of [3H]Thymidine Incorporated/Culture . | |||||||
|---|---|---|---|---|---|---|---|---|
| Controls . | Patients . | |||||||
| 1 . | 2 . | 3 . | 1 . | 2 . | 3 . | 4 . | 5 . | |
| Medium | 2,100 | 1,580 | 1,551 | 3,251 | 1,200 | 1,338 | 1,124 | 357 |
| Anti-CD40 + IL-4 | 11,692 | 10,162 | 37,743 | 82,844 | 9,359 | ND | 23,852 | 10,180 |
| Anti-CD40 + IL-13 | 7,955 | 6,170 | 21,335 | 92,562 | 12,639 | 32,485 | 18,219 | 7,655 |
| B Stimulus . | Controls . | Patients . | ||
|---|---|---|---|---|
| 1 . | 2 . | 2 . | 5 . | |
| Medium | 3,412 | 4,627 | 2,933 | 2,546 |
| Anti-CD40 + IL-4 | 22,269 | 54,459 | 20,917 | 33,878 |
| Anti-CD40 + IL-13 | 14,809 | 39,903 | 18,965 | 33,687 |
| B Stimulus . | Controls . | Patients . | ||
|---|---|---|---|---|
| 1 . | 2 . | 2 . | 5 . | |
| Medium | 3,412 | 4,627 | 2,933 | 2,546 |
| Anti-CD40 + IL-4 | 22,269 | 54,459 | 20,917 | 33,878 |
| Anti-CD40 + IL-13 | 14,809 | 39,903 | 18,965 | 33,687 |
PBMCs (panel A) or T-cell–depleted PBMCs (panel B) (1 × 106 cells/mL) were cultured for 96 hours with medium or with anti-CD40 MoAb (5 μg/mL) plus either IL-4 (100 U/mL) or IL-13 (100 ng/mL). [3H]thymidine incorporation was measured in the last 18 hours of culture. Results shown represent the mean of duplicate cultures.
Abbreviation: ND, not done.